Page 70 - Read Online

Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11 Page 159

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Schizophrenia. Fact sheet on schizophrenia: key facts, symptoms, causes of schizophrenia, WHO; 2022. Available from: https://
www.who.int/news-room/fact-sheets/detail/schizophrenia [Last accessed on 15 June 2023].
2. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J
Clin Psychiatry 2019;80:18com12123. DOI
3. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of
antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-5. DOI PubMed
4. Gören JL, Rose AJ, Smith EG, Ney JP. The business case for expanded clozapine utilization. Psychiatr Serv 2016;67:1197-205. DOI
PubMed
5. Ertugrul A. Clozapine and suicide. Am J Psychiatry 2002;159:323. DOI PubMed
6. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41. DOI
PubMed
7. Verma M, Grover S, Chakrabarti S. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant
schizophrenia. Nord J Psychiatry 2021;75:135-44. DOI PubMed
8. Thien K, O’Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A
literature review. Early Interv Psychiatry 2019;13:18-23. DOI
9. Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS. An evaluation of the variation and underuse of clozapine in
the United Kingdom. Acta Psychiatr Scand 2021;143:339-47. DOI PubMed
10. Bogers JP, Schulte PF, Van Dijk D, Bakker B, Cohen D. Clozapine underutilization in the treatment of schizophrenia: how can
clozapine prescription rates be improved? J Clin Psychopharmacol 2016;36:109-11. DOI PubMed
11. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry
2014;14:102. DOI PubMed PMC
12. Verdoux H, Quiles C, Bachmann CJ, Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: a systematic
review. Schizophr Res 2018;201:10-9. DOI PubMed
13. Verdoux H, Quiles C. Educational needs and psychoeducation interventions in clozapine users: a narrative review. Acta Psychiatr
Scand 2020;142:96-108. DOI PubMed
14. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-
analysis of randomized trials. Am J Psychiatry 1999;156:990-9. DOI PubMed
15. Baig AI, Bazargan-Hejazi S, Ebrahim G, Rodriguez-Lara J. Clozapine prescribing barriers in the management of treatment-resistant
schizophrenia: a systematic review. Medicine 2021;100:e27694. DOI PubMed
16. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv
2000;51:666-8. DOI PubMed
17. Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr
Relat Psychoses 2016;10:163-77. DOI PubMed
18. Chathoth V, Ramamurthy P, Solomon S. Clozapine-induced insulin-resistant hyperglycemia in a diabetic patient. Indian J Psychol
Med 2018;40:375-7. DOI PubMed PMC
19. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr
Scand 2018;138:101-9. DOI
20. Li XH, Zhong XM, Lu L, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive
meta-analysis of observational studies. Psychol Med 2020;50:583-94. DOI
21. Leon J, Sanz EJ, De Las Cuevas C. Data from the world health organization’s pharmacovigilance database supports the prominent
role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 2020;46:1-3. DOI PubMed PMC
22. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012;6:134-44.
PubMed
23. Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 2011;198:247-9. DOI PubMed
24. Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic
review. BJPsych Bull 2019;43:8-16. DOI PubMed PMC
25. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16-24. DOI
PubMed
26. Shah P, Iwata Y, Plitman E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-
resistant schizophrenia: a systematic review. Psychiatry Res 2018;268:114-22. DOI